October 19, 2021
For Immediate Release
Oyster Point Pharma, a Princeton NJ company, has announced the FDA has approved Tyrvaya™ as the first and only nasal spray approved for treating signs and symptoms of Dry Eye Disease.
Guruprasad R. Pattar, MD, PhD, of The Eye Care Institute and Butchertown Clinical Trials, was a principal investigator for the clinical trials leading to the FDA approval of this new treatment option for persons suffering from dry eye disease. Dr. Pattar stated, “this nasal spray gave many of our patients increased comfort during clinical trials here at our facility. The nasal spray will be available soon and it is to be used twice per day per nostril. It is the only approved nasal spray for both signs and symptoms of dry eye disease and is right for many persons who suffer from dry eye disease but find that using eye drops is challenging.”
Jeffrey Nau, Ph.D., MMS, president and CEO of Oyster Point Pharma commented, “The approval of TYRVAYA Nasal Spray marks a milestone for patients and eye care professionals by providing a new drug treatment option for the signs and symptoms of dry eye disease with a differentiated route of administration that is believed to leverage a nerve pathway that can be accessed within the nose.”
This is the 14th FDA approved drug or device for Louisville, KY based Butchertown Clinical Trials. The 13th FDA approval was announced just one day ago. Mark Prussian, CEO, stated there is some disagreement about when dry eye disease was first recognized, but it is generally agreed that the first cases were diagnosed between 1973 and 1995. This relatively new condition has caused increasing discomfort, and sometimes pain, as the use of digital screens, air conditioning, and other environmental changes continue to increase. Delivering eye medication by nasal spray is a novel way to help improve the lives of persons who cannot easily use eye drops. This trial, representing our 14th FDA approval, is just one more way we help improve human health. This spray is expected to be available during November 2021, by prescription only. It will be packaged in a carton with two nasal spray bottles. Each bottle contains a 15 day supply.
For More Information Contact Mark Prussian at Butchertown Clinical Trials
